QUESTIONS

1. What is your diagnosis?
   a. Bullous pemphigoid.
   b. Urticaria.
   c. Subacute cutaneous lupus.
   d. Erythema multiforme.
   e. Urticaria pigmentosa.

© 2015 The Society for Investigative Dermatology
2. How does the ASTERIA I study differ from previous studies of omalizumab for chronic idiopathic urticaria?
   a. Dosing of the drug.
   b. Inclusion criteria.
   c. Duration of the study.
   d. Ability to use additional concurrent drugs.
   e. All of the above.

3. From the results of this study, which of the following is true regarding omalizumab for chronic idiopathic urticaria (CIU) (choose all that apply)?
   a. Improves CIU in a dose-dependent fashion.
   b. Most clinical improvement is experienced soon after initiation.
   c. Maximal benefit was demonstrated with this study.
   d. Placebo effect is most persistent of all treatments.
   e. All of the above.

**TOPIC ARTICLE**

Questions 2 and 3 refer to the following article:

Answers are available as supplementary material at http://dx.doi.org/10.1038/jid.2014.473.